secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001628280-23-023671
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics reports Phase 1 data for FHD-286 in uveal melanoma, will not advance independently
--------------------------------------------------------------------------------

- Phase 1 dose escalation study of FHD-286 in 73 metastatic uveal melanoma patients showed safety and tolerability; most common adverse events were dysgeusia, fatigue, AST increase.
- One patient achieved durable partial response (>16 months on treatment), nine patients had stable disease, and tumor reductions were observed in eight patients.
- Company will not advance FHD-286 in uveal melanoma; plans to initiate combination study with decitabine or cytarabine in relapsed/refractory AML in Q3 2023.
- Preliminary immune modulation markers in tumor microenvironment support combination with checkpoint inhibitors; full results to be presented at future scientific meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/0001628280-23-023671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/fhtx-20230628.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-023671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer